One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
MorphoSys AG logo
MorphoSys AG MOR
report update icon

Quarterly report 2023-Q4
added 07-04-2026

MorphoSys AG Cash Flow 2023-2011 | MOR

Brief overview of MorphoSys AG's cash movements

The comparison covers five available annual reports between 2017 and 2021.

Operating cash flow is negative at -€481.4 million, leaving internal funding capacity weak.

Positive operating cash flow appeared only 1 times out of five; a stable cash profile has not formed.

Overall picture

Taken together, MorphoSys AG's cash flow indicators point to increased dependence on reserves or outside financing.

Annual Cash Flow MorphoSys AG

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-296 M -367 M -481 M 35.3 M -81.1 M -32.8 M -38.4 M -46.6 M - - - - -

All numbers in EUR currency

Quarterly Cash Flow MorphoSys AG

2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-296 M -367 M - - - -481 M - - - 35.3 M - - - -81.1 M - - - -32.8 M - - - -38.4 M - - - -46.6 M - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Cash Flow Statement is one of the three key financial reports of the company MorphoSys AG, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
- - $ 155 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
- - $ 127 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Gilead Sciences Gilead Sciences
GILD
$ 166.01 -0.31 % $ 207 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 22.14 -1.6 % $ 248 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Turning Point Therapeutics Turning Point Therapeutics
TPTX
- -0.13 % $ 3.73 B usaUSA
Orgenesis Orgenesis
ORGS
- -33.86 % $ 61.2 M usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
BELLUS Health BELLUS Health
BLU
- - $ 2.47 B canadaCanada
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
- - $ 13.6 B usaUSA
Marinus Pharmaceuticals Marinus Pharmaceuticals
MRNS
- - $ 29.6 M usaUSA
GeoVax Labs GeoVax Labs
GOVX
$ 1.83 -4.45 % $ 8.35 M usaUSA
Unity Biotechnology Unity Biotechnology
UBX
- -33.41 % $ 3.37 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Tyme Technologies Tyme Technologies
TYME
- 8.07 % $ 54 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
Revance Therapeutics Revance Therapeutics
RVNC
- - $ 309 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
TRACON Pharmaceuticals TRACON Pharmaceuticals
TCON
- -1.38 % $ 46.8 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
- -0.75 % $ 18.7 M danmarkDanmark
9 Meters Biopharma 9 Meters Biopharma
NMTR
- -42.97 % $ 1.05 M usaUSA
Theratechnologies Theratechnologies
THTX
- - $ 83.9 M canadaCanada
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
- -60.05 % $ 125 K usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Sage Therapeutics Sage Therapeutics
SAGE
- - $ 527 M usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
- - $ 121 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 34.99 3.77 % $ 147 M usaUSA
Seelos Therapeutics Seelos Therapeutics
SEEL
- -47.76 % $ 6.27 M usaUSA
Kiromic BioPharma Kiromic BioPharma
KRBP
- 6.61 % $ 3.08 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
- - $ 1.41 B canadaCanada
Gritstone Oncology Gritstone Oncology
GRTS
- 0.42 % $ 213 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA